CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons von Tefferi, A, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R, Hanson, C H, Maffioli, M, Caramazza, D, Passamonti, F, Pardanani, A

Volltext

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms von Abdel-Wahab, O, Pardanani, A, Rampal, R, Lasho, T L, Levine, R L, Tefferi, A

Volltext

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia von Pardanani, A, Lasho, T L, Laborde, R R, Elliott, M, Hanson, C A, Knudson, R A, Ketterling, R P, Maxson, J E, Tyner, J W, Tefferi, A

Volltext

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients von Tefferi, A, Guglielmelli, P, Lasho, T L, Rotunno, G, Finke, C, Mannarelli, C, Belachew, A A, Pancrazzi, A, Wassie, E A, Ketterling, R P, Hanson, C A, Pardanani, A, Vannucchi, A M

Volltext

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact von Tefferi, A, Lasho, T L, Finke, C, Belachew, A A, Wassie, E A, Ketterling, R P, Hanson, C A, Pardanani, A

Volltext

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis von Tefferi, A, Pardanani, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Gangat, N, Finke, C M, Schwager, S, Mullally, A, Li, C-Y, Hanson, C A, Mesa, R, Bernard, O, Delhommeau, F, Vainchenker, W, Gilliland, D G, Levine, R L

Volltext

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis von Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A

Volltext

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms von Pardanani, A, Lasho, T L, Finke, C M, Mai, M, McClure, R F, Tefferi, A

Volltext

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients von Guglielmelli, P, Lasho, T L, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, Biamonte, F, Pardanani, A, Zoi, K, Reiter, A, Duncombe, A, Fanelli, T, Pietra, D, Rumi, E, Finke, C, Gangat, N, Ketterling, R P, Knudson, R A, Hanson, C A, Bosi, A, Pereira, A, Manfredini, R, Cervantes, F, Barosi, G, Cazzola, M, Cross, N C P, Vannucchi, A M, Tefferi, A

Volltext

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates von Tefferi, A, Levine, R L, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Finke, C M, Mullally, A, Li, C-Y, Pardanani, A, Gilliland, D G

Volltext

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML von Tefferi, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Patnaik, M M, Hanson, C A, Pardanani, A, Gilliland, D G, Levine, R L

Volltext

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis von Tefferi, A, Lasho, T L, Abdel-Wahab, O, Guglielmelli, P, Patel, J, Caramazza, D, Pieri, L, Finke, C M, Kilpivaara, O, Wadleigh, M, Mai, M, McClure, R F, Gilliland, D G, Levine, R L, Pardanani, A, Vannucchi, A M

Volltext

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F von Tefferi, A, Jimma, T, Sulai, N H, Lasho, T L, Finke, C M, Knudson, R A, McClure, R F, Pardanani, A

Volltext

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients von Lasho, T L, Finke, C M, Hanson, C A, Jimma, T, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

Calreticulin mutations and long-term survival in essential thrombocythemia von Tefferi, A, Wassie, E A, Lasho, T L, Finke, C, Belachew, A A, Ketterling, R P, Hanson, C A, Pardanani, A, Gangat, N, Wolanskyj, A P

Volltext

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis von Tefferi, A, Lasho, T L, Finke, C, Gangat, N, Hanson, C A, Ketterling, R P, Pardanani, A

Volltext

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients von Patnaik, M M, Hanson, C A, Hodnefield, J M, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera von PARDANANI, A, ASHO, T. L, INKE, C. F, HANSON, C. A, TEFFERI, A

Volltext

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia von Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A

Volltext

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes von Pardanani, A, Finke, C, Lasho, T L, Al-Kali, A, Begna, K H, Hanson, C A, Tefferi, A

Volltext